✨ Free AI Report
NeuroBo Pharmaceuticals, Inc. (now MetaVia Inc.): Key Facts, Business Model & Financial Analysis Read the overview below or get the full interactive report with Cyborg Score, analyst debate audio & saved-company playlists — free, no credit card.
Get Free Report →
Home Research Preview NeuroBo Pharmaceuticals, Inc. (now MetaVia Inc.)
Research Preview

NeuroBo Pharmaceuticals, Inc. (now MetaVia Inc.): Business Overview, Financials & Competitive Analysis

NeuroBo Pharmaceuticals is a clinical-stage biotechnology company focused on transforming cardiometabolic diseases, currently developing DA-1726 for obesity and DA-1241 for Metabolic Dysfunction-Associated Steatohepat...

Analyst-debate audio for NeuroBo Pharmaceuticals, Inc. (now MetaVia Inc.)

AskCyborg analysts argue the bull and bear cases for NeuroBo Pharmaceuticals, Inc. (now MetaVia Inc.) across 11 stress-tested dimensions. Listen on your commute -- faster than reading the 30-page report.

Play the free intro →
Free intro · Pro unlocks the full analyst debate
What's in This Report
NeuroBo Pharmaceuticals, Inc. (now MetaVia Inc.) OverviewStrategic ProfileCompetitive LandscapeIndustry ContextKey facts
Get Interactive Report Freeor start reading below
7/ 10Strong

Cyborg Score thesis

Dual-mechanism obesity candidate with differentiated science enters mid-stage development amid strong GLP-1 market...

Read the full analyst-debate transcript →
Industry Biotechnology/Pharmaceuticals (Clinical-stage)
4 named competitors
4 recent developments
11 analyst dimensions
Synthesized from analyst-debate stress-testing across 11 dimensions and hundreds of data points. Methodology →
Cyborg Score recalibrated: July 6, 2026
AI-Verified Research
30+ Page Report

Get the Latest NeuroBo Pharmaceuticals, Inc. (now MetaVia Inc.) Report

Up-to-date AI-powered research, analyst debate audio & saved-company playlists

Get Current Report Free
✓ No credit card required
or get it by email

NeuroBo Pharmaceuticals, Inc. (now MetaVia Inc.) Overview

Pro stress-test →

NeuroBo Pharmaceuticals is a clinical-stage biotechnology company focused on transforming cardiometabolic diseases, currently developing DA-1726 for obesity and DA-1241 for Metabolic Dysfunction-Associated Steatohepatitis (MASH). The company now operates under the name MetaVia Inc. following a strategic realignment in November 2024.

Strategic Profile

Pro stress-test →

DA-1726 is a dual oxyntomodulin analog that activates GLP1R and GCGR receptors, designed to achieve superior weight loss by reducing food intake while increasing energy expenditure compared to selective GLP1R agonists. The company remains well-funded following a June 2024 financing of up to $70 million.

Competitive Landscape

Pro stress-test →

NeuroBo competes in the crowded GLP-1/glucagon agonist obesity market against established players (Novo Nordisk, Eli Lilly) and emerging dual-mechanism competitors. In MASH, it faces competition from multiple GPR119 agonists and other metabolic disease therapies in development. Differentiation hinges on dual OXM mechanism and clinical efficacy demonstration.

Industry Context

NeuroBo Pharmaceuticals, Inc. (now MetaVia Inc.) operates in Biotechnology/Pharmaceuticals (Clinical-stage).

Key facts

Founded: N/A · Headquarters: Cambridge, US · Employees: N/A · Revenue: N/A · Market cap: N/A

What the analysts stress-tested

The top findings that survived the multi-agent debate for NeuroBo Pharmaceuticals, Inc. (now MetaVia Inc.).

+2 more stress-tested counter-arguments unlock with Pro. Read the full analyst debate →

Recent developments

Material events tracked by the AskCyborg corpus.

Get alerted when NeuroBo Pharmaceuticals, Inc. (now MetaVia Inc.) has a new material development →

Named competitors

Pulled from the analyst-debate framework. Click any competitor to see their Cyborg Score.

Ozempic/WegovyGLP-1 receptor agonist for obesity and diabetes→Mounjaro/ZepboundGLP-1/GIP dual agonist for obesity and diabetes→RetatrutideTriple GLP-1/GIP/glucagon agonist in development→GPR119 agonistsCompeting MASH therapies→

Compare NeuroBo Pharmaceuticals, Inc. (now MetaVia Inc.) with another company

Pick any company in the AskCyborg corpus to see side-by-side Cyborg Scores and insights.

vs
Side-by-side opens in your AskCyborg account

Industry context

NeuroBo Pharmaceuticals, Inc. (now MetaVia Inc.) operates in Biotechnology/Pharmaceuticals (Clinical-stage). See how the rest of the sector scores on the Cyborg framework.

Browse Biotechnology/Pharmaceuticals (Clinical-stage) research →
NEW · MCP server

Ask your AI assistant about NeuroBo Pharmaceuticals, Inc. (now MetaVia Inc.)

Install the free AskCyborg MCP server in Claude, Cursor, Cline, Continue, or Windsurf and ask any of these in-line:

“Compare NeuroBo Pharmaceuticals, Inc. (now MetaVia Inc.) and its top competitor on Cyborg Score”
“What did NeuroBo Pharmaceuticals, Inc. (now MetaVia Inc.) do this quarter?”
“Is NeuroBo Pharmaceuticals, Inc. (now MetaVia Inc.) a defensible business in 5 years?”
Install the MCP server (10 sec) →
Free, anonymous, no API key required

How AskCyborg builds confidence

⚔

Analyst debate, not single-author opinion

Every report is stress-tested by a panel of AI analysts arguing across 11 dimensions. The output is the part of the case that survived pushback.

📊

Recalibrated weekly

The Cyborg Score is recomputed weekly against fresh data. Recent material developments are continuously tracked and surfaced.

🔗

Methodology open at /methodology

The framework, dimensions, and band breakdowns are documented. The same company gets the same score from any analyst running the framework.

🔒

Free tier is free

No credit card to read the research. Pro adds saved-company audio playlists, monitoring, audio briefings on demand, and PDF export for $39/mo annual.

Sources: public filings, regulatory data, news flow, and proprietary analyst signals. Read the methodology →

Frequently asked questions

What does NeuroBo Pharmaceuticals, Inc. (now MetaVia Inc.) do?+
NeuroBo Pharmaceuticals is a clinical-stage biotechnology company focused on transforming cardiometabolic diseases, currently developing DA-1726 for obesity and DA-1241 for Metabolic Dysfunction-Associated Steatohepat...
What is NeuroBo Pharmaceuticals, Inc. (now MetaVia Inc.)'s Cyborg Score?+
NeuroBo Pharmaceuticals, Inc. (now MetaVia Inc.) has a Cyborg Score of 7/10 (Strong). The score synthesizes business model, financials, leadership, competitive position, technology, marketing, and ESG dimensions across hundreds of data points.
Who are NeuroBo Pharmaceuticals, Inc. (now MetaVia Inc.)'s main competitors?+
Named competitors include Ozempic/Wegovy, Mounjaro/Zepbound, Retatrutide, GPR119 agonists. The full competitive landscape is in the AskCyborg report.
How can I get the full NeuroBo Pharmaceuticals, Inc. (now MetaVia Inc.) research report?+
Get the report plus analyst-debate audio at askcyborg.com -- no credit card required for preview access. Pro adds saved-company audio playlists and monitoring.
How current is the NeuroBo Pharmaceuticals, Inc. (now MetaVia Inc.) research?+
The Cyborg Score is recalibrated weekly. Recent developments are tracked continuously and surfaced in every report.

Track NeuroBo Pharmaceuticals, Inc. (now MetaVia Inc.) over time

Pro members get saved-company audio playlists, Cyborg Score recalibrations, and monitoring for material events across the AskCyborg corpus.

See Pro features
From $39/mo annual

Top-scored companies on AskCyborg

Other strong performers across the analyst-debate framework. Click any to see their research report.

9Phnom Penh Water Supply Authority9ESCO Technologies Inc.9Evolution Mining Limited9CoreWeave, Inc.9Nintendo Co., Ltd.9Waste Management, Inc.9CrowdStrike Holdings, Inc.9SK Hynix Inc.9Kweichow Moutai Co., Ltd.9Apple Inc.8Domino's Pizza, Inc.8Pro-Dex, Inc.8Palladyne AI Corp.8Mo-BRUK S.A.8Kuwait Reinsurance Company K.S.C.P.8Red River Bancshares, Inc.8PTC India Limited8IsoEnergy Ltd.